C-peptide vs Mazdutide
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and Mazdutide (IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
| Property | C-peptide | Mazdutide |
|---|---|---|
| Category | Pain Management | Weight Management |
| Full Name | Connecting peptide (C-peptide) | IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist |
| Molecular Weight | 3020.3 Da | ~5,000 Da |
| Half-Life | ~20-30 min | 5-7 days |
| Amino Acids | 31 | 37 |
| Typical Dose | no approved analgesic dose|research-only | 1-6 mg weekly in obesity trials |
| Route | IV|subQ | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 28 |
| Research Status | Pre-clinical | Clinical |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
Mazdutide Benefits
- ✓clinically meaningful weight loss
- ✓better glycemic control
- ✓reduced waist circumference
- ✓improved lipid profile
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
Mazdutide Dosing
Once-weekly SC titration|Dose escalation every 4 weeks|Use with lifestyle modification
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
Mazdutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠constipation
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
Mazdutide
Clinical programs have shown substantial reductions in body weight and improvements in cardiometabolic risk markers. It is a prominent newer dual agonist in the obesity literature.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.